{"organizations": [], "uuid": "2c838a1dd8d8dbf63dd443db287097f9bea0615a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/09/business-wire-celgene-prices-4-point-5-billion-of-senior-unsecured-notes.html", "country": "US", "domain_rank": 767, "title": "Celgene Prices $4.5 Billion of Senior Unsecured Notes", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-09T15:30:00.000+02:00", "replies_count": 0, "uuid": "2c838a1dd8d8dbf63dd443db287097f9bea0615a"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/09/business-wire-celgene-prices-4-point-5-billion-of-senior-unsecured-notes.html", "ord_in_thread": 0, "title": "Celgene Prices $4.5 Billion of Senior Unsecured Notes", "locations": [], "entities": {"persons": [], "locations": [{"name": "n.j.", "sentiment": "none"}], "organizations": [{"name": "celgene corporation", "sentiment": "negative"}, {"name": "celgene", "sentiment": "negative"}, {"name": "citigroup global markets", "sentiment": "none"}, {"name": "juno therapeutics, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of four series of senior unsecured notes for an aggregate principal amount of $4.5 billion. Of these notes, $500 million will mature in 2021 and will bear interest at an annual rate of 2.875 percent, $1.0 billion will mature in 2023 and will bear interest at an annual rate of 3.25 percent, $1.5 billion will mature in 2028 and will bear interest at an annual rate of 3.90 percent and $1.5 billion will mature in 2048 and will bear interest at an annual rate of 4.55 percent. The 2.875 percent notes due 2021, the 3.25 percent notes due 2023, the 3.90 percent notes due in 2028 and the 4.55 percent notes due in 2048 were priced to yield 2.891 percent, 3.303 percent, 3.942 percent and 4.587 percent, respectively.\nCelgene expects to use the net proceeds from the offering to finance a portion of the acquisition of Juno Therapeutics, Inc. and to pay fees and expenses associated therewith and with the offering. The offering is expected to close on February 20, 2018.\nCitigroup Global Markets Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated acted as joint book-running managers and representatives of the several underwriters. A copy of the preliminary prospectus supplement and the accompanying base prospectus, which is filed as part of Celgene’s effective shelf registration statement on Form S-3 filed on October 27, 2016 (File No. 333-214279), may be obtained from any of the representatives by calling Citigroup Global Markets Inc. at 1-800-831-9146, Deutsche Bank Securities Inc. at 1-800-503-4611, J.P. Morgan Securities LLC at 212-834-4533 and Merrill Lynch, Pierce, Fenner & Smith Incorporated at 1-800-294-1322.\nAn electronic copy of the prospectus supplement and the accompanying base prospectus may also be obtained at no charge at the Securities and Exchange Commission’s website at www.sec.gov .\nThis press release does not constitute an offer to sell or a solicitation of an offer to buy the notes described herein, nor shall there be any sale of these notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of such jurisdiction. The offering of the notes will be made only by means of a prospectus supplement and the accompanying base prospectus.\nAbout Celgene\nCelgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com . Follow Celgene on Social Media: @Celgene , Pinterest , LinkedIn , Facebook and YouTube .\nHyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.\nForward-Looking Statements\nThis press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words \"expects,\" \"anticipates,\" \"believes,\" \"intends,\" \"estimates,\" \"plans,\" \"will,\" \"outlook\" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180209005271/en/\nCelgene Corporation\nInvestors:\n908-673-9628\ninvestors@celgene.com\nor\nMedia:\n908-673-2275\nmedia@celgene.com\nSource: Celgene Corporation", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2Fcelgene&esheet=51756120&newsitemid=20180209005271&lan=en-US&anchor=%40Celgene&index=3&md5=4a8e9fc2bd926ff7855f9f23285aa612", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=51756120&newsitemid=20180209005271&lan=en-US&anchor=www.sec.gov&index=1&md5=9a63f807db5df4cab994e06c7dc0c5b3", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2Fcelgene&esheet=51756120&newsitemid=20180209005271&lan=en-US&anchor=YouTube&index=7&md5=0a101347a205c5d1b77d723926aac4ed", "http://www.businesswire.com/news/home/20180209005271/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.pinterest.com%2Fcelgene%2F&esheet=51756120&newsitemid=20180209005271&lan=en-US&anchor=Pinterest&index=4&md5=3faa31e02e0e84a6f80dc56893b5c8bf", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FCelgene&esheet=51756120&newsitemid=20180209005271&lan=en-US&anchor=Facebook&index=6&md5=e13947f2811a04723f77aaa9dc054e6f", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.celgene.com%2F&esheet=51756120&newsitemid=20180209005271&lan=en-US&anchor=www.celgene.com&index=2&md5=2e47772ce6f63d15efc2786853143ec3", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fcelgene&esheet=51756120&newsitemid=20180209005271&lan=en-US&anchor=LinkedIn&index=5&md5=097b9a869a3e71010d552301967f58b5"], "published": "2018-02-09T15:30:00.000+02:00", "crawled": "2018-02-09T16:35:16.001+02:00", "highlightTitle": ""}